Propeller delivers consistent and significant clinical improvements

Propeller’s consistent improvements in disease control and medication adherence are seen across diverse patient populations, settings and geographies. Propeller has been studied in 15+ clinical studies totalling over 2,500 patients and has been deployed in more than 40 commercial programs across the US to date

Talk to our team to learn more

Propeller users see consistent reductions in rescue inhaler use

Reductions in rescue inhaler use translate to better asthma and COPD control, lower healthcare costs, more days free from symptoms and higher patient quality of life

Propeller provides consistent levels of high medication adherence

Propeller programs show an average medication adherence of 46.6%, with many programs showing consistent adherence above 55%, compared to US average medication adherence of 22.1%

Propeller delivers consistent improvements in asthma control

On average, over 50% of patients with uncontrolled asthma achieve controlled status within one year of starting on Propeller. These consistent results are seen across randomized clinical studies and in diverse commercial programs

Positive ROI - Asthma

Uncontrolled asthma is expensive

Patients with uncontrolled asthma cost more each year compared to patients with controlled asthma

Higher direct asthma costs and higher total costs

Talk to our team to learn more

Difference in direct asthma costs per year

(5 studies, n=142, 402)

Cost Savings
(Controlled Asthma vs. Uncontrolled)

Article N Asthma Direct Costs Savinga Total Direct Costs Savings Population
Ivanova et al, 2012 12,632 $893 $4,212 Privately insured patients with moderate or severe persistent asthma, ages 12-64.
Zeiger et al, 2008b,c 96,631 $356 $2,101 Privately insured asthmatic adults and children.
Szefler et al, 2011b 628 $1,359 NA TENOR study patients, with severe asthma or mild / moderate asthma considered difficult-to-treat ages 6-12.
Sawicki et al, 2010c 28,595 $789 NA Privately insured adults and children with asthma-related healthcare utilization or prescriptions.
Sullivan et al, 2007 3,916 $1,251 NA Patients with severe or difficult-to-treat asthma, ages > 12.
Estimated cost savings: $930d $2,100e
ArticleIvanova et al, 2012
N12,632
Asthma Direct Costs Savinga$893
Total Direct Costs Savings$4,212
PopulationPrivately insured patients with moderate or severe persistent asthma, ages 12-64.
ArticleZeiger et al, 2008b,c
N96,631
Asthma Direct Costs Savinga$356
Total Direct Costs Savings$2,101
PopulationPrivately insured asthmatic adults and children.
ArticleSzefler et al, 2011b
N628
Asthma Direct Costs Savinga$1,359
Total Direct Costs SavingsNA
PopulationTENOR study patients, with severe asthma or mild / moderate asthma considered difficult-to-treat ages 6-12.
ArticleSawicki et al, 2010c
N28,595
Asthma Direct Costs Savinga$789
Total Direct Costs SavingsNA
PopulationPrivately insured adults and children with asthma-related healthcare utilization or prescriptions.
ArticleSullivan et al, 2007
N3,916
Asthma Direct Costs Savinga$1,251
Total Direct Costs SavingsNA
PopulationPatients with severe or difficult-to-treat asthma, ages > 12.
$2,101LESS PER YEAR IN TOTAL COSTS (controlled vs. uncontrolled)
Zeiger, et al. 2008 (n=96,631)
  • aAsthma-related direct costs defined as expenses from pharmaceuticals, inpatient hospitalizations, emergency department visits, and (except in Zeiger et al (2008) and Sawicki et al (2010)) unscheduled outpatient visits.
  • bCost in uncontrolled is a weighted average of multiple uncontrolled groups.
  • cCosts do not include outpatient medical visits.
  • dSavings averaged across all studies.
  • eFinal cost savings drawn from Zieger et al. (2008)

Propeller improves asthma control

Analyzing all patients on the Propeller System, we see that daily rescue inhaler use drops rapidly and persistently, with a 79% average reduction in rescue inhaler use at 1 year

Improving asthma control with Propeller yields positive ROI

Assumes 75% of people with uncontrolled asthma enrolled. Customers should see an average ROI of 2-5x depending on % improvement seen and use of direct vs. total costs Talk to our team to learn more

50% improvement seen across all patients on Propeller.

60% improvement seen in 495 patient randomized controlled clinical study.